Korro Bio Analyst Price Targets - Benzinga

Korro Bio Inc

KRRONASDAQ

Trade with Public

Trade with Public

$9.97

0.333.42%

最終更新: Oct 2, 4:00 PM

$9.64

N/A

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Korro Bio Analyst Price Targets - Benzinga

Korro Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Korro Bio (KRRO).

Price Target Range — 13 Quarters

Analyst Consensus — 12 Analysts

10Buy

2Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$37Upside to Avg. PT+278.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$15
Aug 20, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$15
May 19, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$20→$15
May 18, 2026	Citigroup	Yigal Nochomovitz	Initiate	Buy	$21
Mar 13, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$21→$22
Mar 13, 2026	Raymond James	Steven Seedhouse	Upgrade	Market Perform→Outperform	$23
Feb 19, 2026	Clear Street	Bill Maughan	Upgrade	Hold→Buy	$10→$18
Feb 17, 2026	William Blair	Myles Minter	Upgrade	Market Perform→Outperform	—
Jan 29, 2026	Piper Sandler	Yasmeen Rahimi	Upgrade	Neutral→Overweight	$11→$30
Jan 29, 2026	Chardan Capital	Keay Nakae	Upgrade	Neutral→Buy	$7→$15
Jan 29, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Upgrade	Neutral→Buy	$20
Jan 28, 2026	Oppenheimer	Kostas Biliouris	Upgrade	Perform→Outperform	$22
Jan 28, 2026	Cantor Fitzgerald	Steve Seedhouse	Upgrade	Neutral→Overweight	$21
Nov 14, 2025	Jones Trading	Catherine Novack	Downgrade	Buy→Hold	—
Nov 13, 2025	William Blair	Myles Minter	Downgrade	Outperform→Market Perform	—
Nov 13, 2025	RBC Capital	Luca Issi	Downgrade	Outperform→Sector Perform	$85→$8
Nov 13, 2025	Chardan Capital	Keay Nakae	Downgrade	Buy→Neutral	$25→$7
Nov 13, 2025	Cantor Fitzgerald	Steve Seedhouse	Downgrade	Overweight→Neutral	—
Nov 13, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Downgrade	Buy→Neutral	—
Oct 31, 2025	Clear Street	Bill Maughan	Initiate	Buy	$93

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Korro Bio, Lowers Price Target to $15

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Korro Bio (NASDAQ:KRRO) with a Buy and lowers the price target from $20 to $15.

Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On Korro Bio with Buy Rating, Announces Price Target of $21

Citigroup analyst Yigal Nochomovitz initiates coverage on Korro Bio (NASDAQ:KRRO) with a Buy rating and announces Price Target of $21.

Benzinga Newsdesk

Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook

Korro Bio stock rises after earnings as analysts upgrade outlook, highlight new drug candidate, and long-term growth plans.

Vandana Singh

PRO
Cantor Fitzgerald Maintains Overweight on Korro Bio, Raises Price Target to $22

Cantor Fitzgerald analyst Steve Seedhouse maintains Korro Bio (NASDAQ:KRRO) with a Overweight and raises the price target from $21 to $22.

Benzinga Newsdesk